skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.08d (Release date: 2017-08-28)
SearchBox Top
SearchBox Bottom
Modified Vaccinia Ankara (Bavarian Nordic)-HER2 Vaccine (Code C71758)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Modified Vaccinia Ankara (Bavarian Nordic)-HER2 Vaccine

Definition: A cancer vaccine consisting of a proprietary, recombinant modified vaccinia Ankara (MVA) viral vector encoding an epitope of human epidermal growth factor receptor 2 (HER2) with potential antineoplastic activity. Upon administration, modified vaccinia Ankara (Bavarian Nordic)-HER2 vaccine may stimulate the host immune system to mount humoral and cytotoxic T lymphocyte responses against HER2-expressing tumor cells, resulting in tumor cell lysis. HER2, also known as ErbB-2, is a tyrosine kinase growth factor receptor and a member of the epidermal growth factor receptor family; it plays a significant role in the pathogenesis of some breast cancers.

Display Name: Modified Vaccinia Ankara (Bavarian Nordic)-HER2 Vaccine

Label: Modified Vaccinia Ankara (Bavarian Nordic)-HER2 Vaccine

NCI Thesaurus Code: C71758 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL376123  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Modified Vaccinia Ankara (Bavarian Nordic)-HER2 Vaccine

External Source Codes: 
PDQ Closed Trial Search ID 558806
PDQ Open Trial Search ID 558806 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C71758
Contributing_Source CTRP
Legacy_Concept_Name MVA-BN-HER2
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom